BRPI0914652A2 - compostos e composições como inibidores de quinase - Google Patents
compostos e composições como inibidores de quinaseInfo
- Publication number
- BRPI0914652A2 BRPI0914652A2 BRPI0914652A BRPI0914652A BRPI0914652A2 BR PI0914652 A2 BRPI0914652 A2 BR PI0914652A2 BR PI0914652 A BRPI0914652 A BR PI0914652A BR PI0914652 A BRPI0914652 A BR PI0914652A BR PI0914652 A2 BRPI0914652 A2 BR PI0914652A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- compounds
- kinase inhibitors
- kinase
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7558308P | 2008-06-25 | 2008-06-25 | |
US15543409P | 2009-02-25 | 2009-02-25 | |
PCT/US2009/048428 WO2010002655A2 (en) | 2008-06-25 | 2009-06-24 | Compounds and compositions as kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0914652A2 true BRPI0914652A2 (pt) | 2017-06-06 |
Family
ID=41349515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0914652A BRPI0914652A2 (pt) | 2008-06-25 | 2009-06-24 | compostos e composições como inibidores de quinase |
Country Status (29)
Country | Link |
---|---|
US (2) | US8519129B2 (pt) |
EP (1) | EP2318392A2 (pt) |
JP (1) | JP5508412B2 (pt) |
KR (1) | KR101432352B1 (pt) |
CN (1) | CN102112467B (pt) |
AR (1) | AR072787A1 (pt) |
AU (1) | AU2009264934B2 (pt) |
BR (1) | BRPI0914652A2 (pt) |
CA (1) | CA2729495C (pt) |
CL (1) | CL2009001476A1 (pt) |
CO (1) | CO6351787A2 (pt) |
CR (1) | CR20110028A (pt) |
DO (1) | DOP2010000397A (pt) |
EA (1) | EA020730B1 (pt) |
EC (1) | ECSP11010784A (pt) |
GE (1) | GEP20125564B (pt) |
HN (1) | HN2010002733A (pt) |
IL (1) | IL210124A0 (pt) |
MA (1) | MA32497B1 (pt) |
MX (1) | MX2010014039A (pt) |
NI (1) | NI201000219A (pt) |
NZ (1) | NZ590602A (pt) |
PA (1) | PA8834001A1 (pt) |
PE (1) | PE20100087A1 (pt) |
SV (1) | SV2010003776A (pt) |
TW (1) | TW201000466A (pt) |
UY (1) | UY31929A (pt) |
WO (1) | WO2010002655A2 (pt) |
ZA (1) | ZA201100344B (pt) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8440681B2 (en) | 2007-08-28 | 2013-05-14 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
UY31929A (es) * | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
US8933227B2 (en) | 2009-08-14 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Selective synthesis of functionalized pyrimidines |
JP5539518B2 (ja) | 2009-08-14 | 2014-07-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 2−アミノ−5−トリフルオロメチルピリミジン誘導体の位置選択的調製 |
US20130005733A1 (en) | 2010-03-09 | 2013-01-03 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
JP5607241B2 (ja) | 2010-05-21 | 2014-10-15 | ケミリア・エービー | 新規ピリミジン誘導体 |
MA34299B1 (fr) | 2010-06-04 | 2013-06-01 | Hoffmann La Roche | Dérivés d'aminopyrimidine au titre de modulateurs de lrrk2 |
NO2638031T3 (pt) | 2010-11-10 | 2018-03-10 | ||
WO2012097479A1 (en) * | 2011-01-21 | 2012-07-26 | Abbott Laboratories | Bicyclic inhibitors of anaphastic lymphoma kinase |
MX2013010898A (es) | 2011-03-24 | 2013-12-06 | Chemilia Ab | Novedoso derivados de la pirimidina. |
CN106946795B (zh) | 2011-04-22 | 2020-06-02 | 西格诺药品有限公司 | 取代的二氨基甲酰胺和二氨基甲腈嘧啶,其组合物,和用其治疗的方法 |
EP2554544A1 (en) * | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
US8969361B2 (en) * | 2012-04-20 | 2015-03-03 | Annji Pharmaceutical Co., Ltd. | Cyclopropanecarboxylate esters of purine analogues |
AU2012382373A1 (en) | 2012-06-12 | 2014-12-11 | Abbvie Inc. | Pyridinone and pyridazinone derivatives |
ES2728008T3 (es) | 2012-11-06 | 2019-10-21 | Shanghai Fochon Pharmaceutical Co Ltd | Inhibidores de quinasa ALK |
CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
WO2015094803A1 (en) * | 2013-12-16 | 2015-06-25 | Calitor Sciences, Llc | Substituted heteroaryl compounds and methods of use |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
NZ715903A (en) | 2014-01-30 | 2017-06-30 | Signal Pharm Llc | Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
CN106103484B (zh) | 2014-03-14 | 2021-08-20 | 诺华股份有限公司 | 针对lag-3的抗体分子及其用途 |
US10023593B2 (en) * | 2014-05-30 | 2018-07-17 | Beijing Pearl Biotechnology Limited Liability Company | ALK kinase inhibitor, and preparation method and uses thereof |
MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
JP6877339B2 (ja) | 2014-10-14 | 2021-05-26 | ノバルティス アーゲー | Pd−l1に対する抗体分子およびその使用 |
WO2016100310A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide |
WO2016100308A1 (en) | 2014-12-16 | 2016-06-23 | Signal Pharmaceuticals, Llc | Methods for measurement of inhibition of c-jun n-terminal kinase in skin |
EP3233918A1 (en) | 2014-12-19 | 2017-10-25 | Novartis AG | Combination therapies |
CN105777616B (zh) * | 2014-12-26 | 2018-12-07 | 上海医药工业研究院 | 色瑞替尼的合成中间体及其制备方法 |
US20180022710A1 (en) | 2015-01-29 | 2018-01-25 | Signal Pharmaceuticals, Llc | Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide |
SG11201706756VA (en) | 2015-03-10 | 2017-09-28 | Aduro Biotech Inc | Compositions and methods for activating "stimulator of interferon gene" -dependent signalling |
CA2993173C (en) | 2015-07-24 | 2023-10-03 | Celgene Corporation | Methods of synthesis of (1r,2r,5r)-5-amino-2-methylcyclohexanol hydrochloride and intermediates useful therein |
LT3317301T (lt) | 2015-07-29 | 2021-07-26 | Novartis Ag | Kombinuotos terapijos, apimančios antikūno molekules prieš lag-3 |
EP3316902A1 (en) | 2015-07-29 | 2018-05-09 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
DK3370768T3 (da) | 2015-11-03 | 2022-03-21 | Janssen Biotech Inc | Antistoffer som specifikt binder pd-1 og anvendelser deraf |
MX2018007423A (es) | 2015-12-17 | 2018-11-09 | Novartis Ag | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas. |
EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
WO2020069208A1 (en) * | 2018-09-27 | 2020-04-02 | The Regents Of The University Of California | Prevention and treatment of osteoarthritis by inhibition of insulin growth factor-1 signaling |
EP3985000A4 (en) * | 2019-06-28 | 2022-08-31 | Chengdu Zenitar Biomedical Technology Co., Ltd. | 2,4-DISUBSTITUTED PYRIMIDI DERIVATIVE, PROCESS FOR ITS PREPARATION AND ITS USES |
CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
GB201915618D0 (en) | 2019-10-28 | 2019-12-11 | Univ Oslo | ALK inhibitors for treatment of ALK-negative cancer and antibody-mediated diseases |
CN114685616A (zh) * | 2020-12-31 | 2022-07-01 | 哈尔滨三联药业股份有限公司 | 醋酸曲普瑞林的合成方法 |
CN114276331B (zh) * | 2022-01-04 | 2023-05-23 | 中国药科大学 | 4-氨基哌啶类化合物及其制备方法、药物组合物和应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2274634T3 (es) | 1998-08-29 | 2007-05-16 | Astrazeneca Ab | Compuestos de pirimidina. |
WO2001007027A2 (en) | 1999-07-22 | 2001-02-01 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives for the treatment of viral diseases |
HUP0301117A3 (en) | 2000-02-17 | 2004-01-28 | Amgen Inc Thousand Oaks | Imidazole derivatives kinase inhibitors, their use, process for their preparation and pharmaceutical compositions containing them |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
US6939874B2 (en) | 2001-08-22 | 2005-09-06 | Amgen Inc. | Substituted pyrimidinyl derivatives and methods of use |
WO2003026666A1 (en) | 2001-09-26 | 2003-04-03 | Bayer Pharmaceuticals Corporation | 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors |
GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
WO2004087698A2 (en) | 2003-03-25 | 2004-10-14 | Vertex Pharmaceuticals Incorporated | Thiazoles useful as inhibitors of protein kinases |
PL1656372T3 (pl) | 2003-07-30 | 2013-08-30 | Rigel Pharmaceuticals Inc | Związki 2,4-pirymidynodiaminy do stosowania w leczeniu lub zapobieganiu chorobom autoimmunologicznym |
ES2380206T3 (es) | 2003-08-15 | 2012-05-09 | Novartis Ag | 2,4-Pirimidindiaminas útiles para el tratamiento de enfermedades neoplásicas, trastornos inflamatorios y del sistema inmunitario |
GB0321710D0 (en) | 2003-09-16 | 2003-10-15 | Novartis Ag | Organic compounds |
JP2007505858A (ja) * | 2003-09-18 | 2007-03-15 | ノバルティス アクチエンゲゼルシャフト | 増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン |
JP5208516B2 (ja) * | 2004-12-30 | 2013-06-12 | エグゼリクシス, インコーポレイテッド | キナーゼモジュレーターとしてのピリミジン誘導体および使用方法 |
US20060270694A1 (en) * | 2005-05-03 | 2006-11-30 | Rigel Pharmaceuticals, Inc. | JAK kinase inhibitors and their uses |
KR100700676B1 (ko) | 2005-06-24 | 2007-03-28 | (주) 비엔씨바이오팜 | 6―(4―치환된―아닐리노)피리미딘 유도체, 그 제조방법및 이를 포함하는 항바이러스용 약학적 조성물 |
WO2007031829A2 (en) | 2005-09-15 | 2007-03-22 | Orchid Research Laboratories Limited | Novel pyrimidine carboxamides |
RU2448959C2 (ru) | 2005-11-01 | 2012-04-27 | Таргеджен, Инк. | Би-арил-мета-пиримидиновые ингибиторы киназы |
CA2656290A1 (en) * | 2006-07-05 | 2008-01-10 | Exelixis, Inc. | Methods of using igf1r and abl kinase modulators |
CL2007002231A1 (es) | 2006-08-02 | 2008-04-11 | Basf Ag | Uso de compuestos derivados de 5-(het) arilpirimidina para combatir hongos daninos; compuestos derivados de 5-(het) arilpirimidina; agente fungicida; y agente farmaceutico. |
AU2007351498B2 (en) | 2006-08-15 | 2012-04-05 | Xenon Pharmaceuticals Inc. | Organic compounds |
ES2555803T3 (es) | 2006-10-23 | 2016-01-08 | Cephalon, Inc. | Fusión de derivados bicíclicos 2,4-diaminopirimidina como utilizar inhibidores ALK y c-Met |
AU2007333394C1 (en) | 2006-12-08 | 2011-08-18 | Novartis Ag | Compounds and compositions as protein kinase inhibitors |
EP2537830A1 (en) | 2006-12-08 | 2012-12-26 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
WO2008083465A1 (en) | 2007-01-08 | 2008-07-17 | University Health Network | Pyrimidine derivatives as anticancer agents |
WO2009017838A2 (en) | 2007-08-01 | 2009-02-05 | Exelixis, Inc. | Combinations of jak-2 inhibitors and other agents |
US8440681B2 (en) | 2007-08-28 | 2013-05-14 | Irm Llc | 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors |
PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
KR101247840B1 (ko) | 2008-02-22 | 2013-03-26 | 에프. 호프만-라 로슈 아게 | 아밀로이드 베타 조절제 |
US8445505B2 (en) | 2008-06-25 | 2013-05-21 | Irm Llc | Pyrimidine derivatives as kinase inhibitors |
UY31929A (es) * | 2008-06-25 | 2010-01-05 | Irm Llc | Compuestos y composiciones como inhibidores de cinasa |
-
2009
- 2009-06-23 UY UY0001031929A patent/UY31929A/es not_active Application Discontinuation
- 2009-06-23 PE PE2009000902A patent/PE20100087A1/es not_active Application Discontinuation
- 2009-06-24 KR KR1020117001746A patent/KR101432352B1/ko not_active IP Right Cessation
- 2009-06-24 NZ NZ590602A patent/NZ590602A/en not_active IP Right Cessation
- 2009-06-24 EP EP09736712A patent/EP2318392A2/en not_active Withdrawn
- 2009-06-24 GE GEAP200912072A patent/GEP20125564B/en unknown
- 2009-06-24 US US13/000,955 patent/US8519129B2/en not_active Expired - Fee Related
- 2009-06-24 CA CA2729495A patent/CA2729495C/en not_active Expired - Fee Related
- 2009-06-24 TW TW098121260A patent/TW201000466A/zh unknown
- 2009-06-24 WO PCT/US2009/048428 patent/WO2010002655A2/en active Application Filing
- 2009-06-24 JP JP2011516576A patent/JP5508412B2/ja not_active Expired - Fee Related
- 2009-06-24 AU AU2009264934A patent/AU2009264934B2/en not_active Ceased
- 2009-06-24 EA EA201100077A patent/EA020730B1/ru not_active IP Right Cessation
- 2009-06-24 CN CN200980129642.9A patent/CN102112467B/zh not_active Expired - Fee Related
- 2009-06-24 BR BRPI0914652A patent/BRPI0914652A2/pt not_active IP Right Cessation
- 2009-06-24 MX MX2010014039A patent/MX2010014039A/es not_active Application Discontinuation
- 2009-06-24 CL CL2009001476A patent/CL2009001476A1/es unknown
- 2009-06-25 AR ARP090102347A patent/AR072787A1/es not_active Application Discontinuation
- 2009-06-25 PA PA20098834001A patent/PA8834001A1/es unknown
-
2010
- 2010-12-16 NI NI201000219A patent/NI201000219A/es unknown
- 2010-12-20 IL IL210124A patent/IL210124A0/en unknown
- 2010-12-21 SV SV2010003776A patent/SV2010003776A/es unknown
- 2010-12-21 DO DO2010000397A patent/DOP2010000397A/es unknown
- 2010-12-22 HN HN2010002733A patent/HN2010002733A/es unknown
-
2011
- 2011-01-12 CR CR20110028A patent/CR20110028A/es not_active Application Discontinuation
- 2011-01-13 ZA ZA2011/00344A patent/ZA201100344B/en unknown
- 2011-01-21 MA MA33549A patent/MA32497B1/fr unknown
- 2011-01-25 CO CO11008053A patent/CO6351787A2/es active IP Right Grant
- 2011-01-25 EC EC2011010784A patent/ECSP11010784A/es unknown
-
2013
- 2013-07-23 US US13/948,356 patent/US8859574B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0914652A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0912668A2 (pt) | composto e composições como inibidores de quinase | |
LTPA2019510I1 (lt) | Fosforo dariniai kaip kinazių inhibitoriai | |
LTPA2019006I1 (lt) | Junginiai ir kompozicijos kaip proteinkinazės inhibitoriai | |
BRPI0906973A2 (pt) | Compostos e composições como inibidores de cinase. | |
BRPI0911228A2 (pt) | compostos e composições como inibidores de proteínas quinase | |
BRPI0910979A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0920135A2 (pt) | imidazopiridazinacarbonitrilos úteis como inibidores de quinase | |
BRPI0913879A2 (pt) | fenilpirazinonas como inibidores de quinase | |
BRPI0908849A2 (pt) | Composto e composições como c-kit e inibidores de pdgfr quinase | |
BRPI0811516A2 (pt) | Compostos e composições como inibidores de c-kit e pdgfr cinase | |
BRPI0719797A2 (pt) | compostos e composições como inibidores de proteína cinase | |
BRPI0914545A2 (pt) | compostos e composições como inibidores de quinase | |
BRPI0811065A2 (pt) | Indazóis 5-heteroaril substituídos como inibidores de quinase | |
BRPI0913580A2 (pt) | pirrolopiridinas como inibidores de quinase | |
BR112012004448A2 (pt) | "compostos e composições como inibidores de proteína cinase" | |
DK2634231T3 (da) | Sammensætninger | |
BRPI0908494A2 (pt) | Inibidores de pirrolopirazina quinase | |
BRPI0912475A8 (pt) | compostos como inibidores de quinase | |
BRPI0906749A2 (pt) | Composição | |
BRPI0820544A2 (pt) | 4-pirazolil-n-arilpirimidin-2-aminas e pirazolil-n-heteroarilpirimidin-2-aminas como inibidores de janus cinase | |
BRPI0913808A2 (pt) | composição | |
BRPI0918846A2 (pt) | inibidores de cinase heterocíclica | |
ATE519763T1 (de) | Pyrrolopyrazin-kinasehemmer | |
BRPI0813499A2 (pt) | Compostos úteis como inibidores da quinase raf |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |